Latest Conference Articles

Meredith Ayers, CPhT, pharmacy technician at Bremo Pharmacy and presenter at the annual NCPA Convention 2021, discusses the expanding role of pharmacy technicians.

Pezzino discussed new specific prescriptions and treatments compared to current treatment modalities, indications and routes of administration of new drugs in the community setting, and important pharmacokinetic properties of these new drugs.

Ching discussed topics such as additional testing services, recommendations for point-of-care services, and strategies to help increase point-of-care testing services.

Anjanette Wyatt, PharmD, said pharmacists can play a major role in helping patients distinguish trustworthy facts from misinformation.

National Community Pharmacists Association (NCPA) President Brian Caswell, RPh, said he is incredibly proud of the work community pharmacists have done over the past year.

Jameshia Below, PharmD, assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains how oncologic emergencies present in patients, and how each type can be recognized.

Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains what oncologic emergencies are and how they are classified.

Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what the role of the pharmacist is during the treatment of patients with advanced cutaneous T cell lymphoma.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.

Risk stratification for survival should not dictate treatment, but stratification for thrombosis risk should play an important role in treatment decisions.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, describes some of the challenges providers face during the treatment of patients with advanced cutaneous T cell lymphoma and how to address them.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, provides an overview of key trials that have been conducted in the advanced cutaneous T cell lymphoma space in recent years.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.

Pharmacy Times spoke with Dr. Bradley Monk, investigator for KEYNOTE-826, #LBA2, which was presented at the ESMO Congress 2021, about the study and its importance to the world of cervical cancer.

A presentation at the Society of Hematologic Oncology 2021 Annual Meeting reviewed the treatment of amyloidosis in multiple myeloma.

Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines.

With CAR T-cell therapies showing promise for follicular lymphoma and marginal zone lymphoma, clinicians must weigh toxicity and tolerability almost as strongly as efficacy because patients can live years with these diseases

The efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation.

Because asparaginase is used exclusively in ALL, most adult oncologists do not administer it routinely.

Doug Long, vice president of industry relations at IQVIA, and Scott Biggs, director of supplier services, discussed their session at the 2021 National Association of Chain Drug Stores (NACDS) Total Store Expo titled "Pharmaceutical Trends, Issues, and Forecasts."

Pharmacy Times spoke with Dr. Trishia Shaw, the Clinical Assistant Professor of Pharmacy Practice at Chicago State University College of Pharmacy, on her presentation at the NPhA conference titled “Who’s your Provider”—Updates in Provider Status for Pharmacists.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, assistant professor of pharmacy practice at Loma Linda University School of Pharmacy, discusses the importance of Black pharmacists in creating equitable access to COVID-19 vaccinations.

Thomas Maggio, MBA, public affairs and engagement manager at AACP, discussed his presentation assessing the Opioid-Related Activity Database and its impact in showing the efforts of pharmacists and student pharmacists to fight the opioid epidemic.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss how to manage the logistical challenges that arise during the administration of CAR T therapy in inpatient and outpatient settings for patients with multiple myeloma.